Kronos’ Bischofberger Turns To Gilead SYK Inhibitors To Jump Start R&D

Two years after Bischofberger left Gilead for Kronos, he called upon former colleagues to acquire a SYK inhibitor program for a genetically defined subset of acute myelogenous leukemia.